| Reference |
 |
Adjuvant: NSABP B46-I
| Title |
|
A phase III clinical trial comparing the combination of TC plus Bevacizumab to TC alone and to TAC for women with node-positive or high-risk node-negative, HER2-negative breast cancer
| Description |
|
Treatment Plan
Patients
will be randomized to one of three treatment regimens: Group 1: 6 cycles
of TAC every 21 days, Group 2: 6 cycles of TC every 21 days and Group
3: 6 cycles of TCB every 21 days with Bevacizumab
therapy continuing every 21 days after completion of chemotherapy until 1 year
following the first dose. Pegfilgrastim or Filgrastim is required for Group 1 patients and optional
for Groups 2 and 3. Patients will also receive adjuvant radiation therapy as
clinically indicated and endocrine therapy for hormone receptor-positive
tumors.
Basic Eligibility Criteria
§
Tumor
must be unilateral invasive adenocarcinoma of the
breast on histologic examination
§
Breast
cancer must be HER2-Negative
§
Pt
must have undergone either a total mastectomy or breast-conserving surgery
Ineligibility Criteria
§
Chemotherapy
for current diagnosed cancer prior to randomization
§
Definitive
clinical or radiologic evidence of metastatic disease
§
T4 tumors including inflammatory breast cancer
| Additional Info |
|
No additional info available
|
